(State or other jurisdiction of | (Commission File Number) | (I.R.S. Employer | ||||||
incorporation or organization) | Identification No.) |
(Address of principal executive offices) | (Zip Code) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
LIGAND PHARMACEUTICALS INCORPORATED | |||||
Date: January 5, 2024 | By: /s/ Andrew Reardon Name: Andrew Reardon Title: Chief Legal Officer and Secretary |
Cover Page |
Jan. 05, 2024 |
---|---|
Cover [Abstract] | |
Entity Central Index Key | 0000886163 |
Amendment Flag | false |
Document Type | 8-K |
Document Period End Date | Jan. 05, 2024 |
Entity Registrant Name | LIGAND PHARMACEUTICALS INC |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-33093 |
Entity Tax Identification Number | 77-0160744 |
Entity Address, Address Line One | 3911 Sorrento Valley Boulevard, Suite 110 |
Entity Address, City or Town | San Diego |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92121 |
City Area Code | 858 |
Local Phone Number | 550-7500 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Trading Symbol | LGND |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
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end
%!\Z,B&_T;!C^"==4+/CVT\
M'P])$O(60AWG5(@;L\&!6L?52>W.^R,ROR5[O4:?;P^*(0!]A/5^'.;^(%-8
ME"E,S11FERP>3T0T@0"6JQN++! -2>QLTD5X1;(!QK-D#IW,DO1G&@X-,)C[
M@# [PD;/^0&3_5U@<*I2<&K0-,-.282^,(-/^<4^@X5SPM:NVSFX=ADB7(YO
M)NB%'LAP=OL67._2=<5!]P"0@!S6ZZ)SS#WOO$0U.S%P^H#J+*!2["'M